Drug Approval | October 04, 2021
Lilly to transfer rights of two diabetes drugs to Cipla in India
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
_256_384.png)
MTL, with over 40 years of experience in packaging, caters to the requirements of the FMCG, F&B, homecare, personal care, agrochemicals, pharmaceutical, and liquor industries
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Board approves fundraise of Rs 1500 crore
Turnover of API division of ISLL stood at Rs 856.58 crore
Subscribe To Our Newsletter & Stay Updated
